Oncoinvent's Radspherin® Trial Hits Key Milestone in Ovarian Cancer Fight

OSLO, Norway – June 18, 2026 – In the high-stakes world of oncology development, progress is measured in milestones. For Norwegian radiopharmaceutical firm Oncoinvent, a critical milestone was just passed, offering a significant signal of hope for patients with one of the most challenging forms of ovarian cancer. The company announced it has reached 50% patient enrollment in its pivotal Phase 2 trial for Radspherin®, an innovative therapy aimed at eradicating residual cancer cells after surgery.

This achievement is more than just a number; it represents accelerating momentum for a treatment that could redefine care for patients with peritoneal metastases—a common and often deadly progression of ovarian cancer where treatment options are painfully limited. The rapid pace of recruitment not only de-risks the clinical timeline but also underscores the urgent need and clinical enthusiasm for novel approaches in this difficult-to-treat disease.

Clinical Momentum and Growing Confidence

Oncoinvent confirmed that 54 patients are now enrolled in the randomized, controlled Phase 2 study, representing half of the total planned trial population. The pace of recruitment has surged in 2026, with the 28 patients enrolled so far this year already surpassing the total for all of 2025. This acceleration is a testament to the company's operational execution, having opened four new trial sites this year, bringing the total to ten hospitals across the United States, Europe, and the United Kingdom.

"Reaching the halfway point for recruitment in our Phase 2 trial is an important milestone for Oncoinvent and reflects the strong commitment of investigators and study sites," said Oystein Soug, CEO of Oncoinvent, in a statement. "We are pleased to see the steps taken to accelerate recruitment translating into the strong enrollment momentum seen in 2026."

This operational success is crucial. Clinical trial recruitment is a notorious bottleneck in drug development, especially in oncology. The ability to efficiently enroll patients speaks volumes about the perceived promise of the therapy among clinicians and the well-managed expansion of the trial's global footprint. The study's primary goal is to determine if a single, post-surgical dose of Radspherin® can improve progression-free survival compared to the current standard of care.

The Science: A Targeted Alpha-Particle Strike

What makes Radspherin® a compelling candidate is its elegant and potent mechanism. It is a form of targeted alpha therapy, a burgeoning class of radiopharmaceuticals designed to deliver a powerful, localized dose of radiation directly to cancer cells while sparing healthy tissue.

The therapy consists of microscopic calcium carbonate particles that carry radium-224, a potent alpha-emitting isotope. Following surgery to remove visible tumors, Radspherin® is instilled directly into the abdominal (peritoneal) cavity. The microparticles distribute throughout the cavity, creating a therapeutic field. As radium-224 decays, it releases high-energy alpha particles. These particles are like microscopic wrecking balls, traveling only a few cell diameters—less than 0.1 mm—before unleashing their energy. This short path length is key; it means the destructive power is concentrated on any remaining microscopic cancer cells floating in the cavity, causing lethal double-stranded DNA breaks, while minimizing damage to nearby healthy organs.

Furthermore, Radspherin®'s action is "receptor-independent," meaning it doesn't need to find a specific protein on the cancer cell's surface to work. This broadens its potential applicability and overcomes a common hurdle for many targeted therapies.

Addressing a Critical Unmet Need in Ovarian Cancer

The context for this trial is one of dire need. For women with ovarian cancer that has spread to the peritoneum, the prognosis is often poor. The standard treatment involves aggressive cytoreductive surgery (CRS) to remove all visible tumor deposits, followed by chemotherapy. While this can be effective, the invisible enemy—microscopic residual disease—frequently leads to recurrence.

Data shows that even with the best standard of care, peritoneal recurrence rates can be as high as 55-60% within two years. This is the challenge Radspherin® was designed to solve: to be a "clean-up" therapy that eradicates the seeds of recurrence left behind after surgery. The FDA recognized this significant potential in July 2024, granting Radspherin® Fast Track Designation, a move intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

A Foundation of Promising Data

The confidence expressed by investigators and the company is not without foundation. The current Phase 2 trial builds on a bedrock of encouraging earlier-phase data. A Phase 1 study in ovarian cancer patients, with results published in the peer-reviewed journal Gynecologic Oncology, demonstrated that Radspherin® was well tolerated, with no dose-limiting toxicities observed at the recommended 7MBq dose. More importantly, final 24-month data from that study showed a peritoneal recurrence rate of just 10% in patients receiving the target dose—a dramatic reduction from the expected standard-of-care rate.

Similar success was seen in a Phase 1/2a study for peritoneal metastases from colorectal cancer, where Radspherin® was administered after surgery and heated intraperitoneal chemotherapy (HIPEC). At 18 months, only 27.8% of patients had experienced peritoneal recurrence, compared to a historical rate of around 50%. These consistent safety and efficacy signals across multiple studies provide a strong rationale for the ongoing Phase 2 evaluation.

Navigating the Biotech Gauntlet

While the clinical news is positive, Oncoinvent operates within the unforgiving landscape of clinical-stage biotechnology. The company, which is listed on the Euronext Growth Oslo, is burning through cash to fund these expensive trials, a typical and necessary part of the drug development process. Financial analyses show the company holds more cash than debt and its liquid assets cover short-term obligations, but the pressure to deliver is immense. The company's stock has faced headwinds over the past year, reflecting the broader market's volatility and the inherent risks of biotech investing.

However, the recent clinical momentum provides a powerful counter-narrative. Each milestone achieved, from FDA designations to accelerated patient recruitment, serves to de-risk the asset and build value. For investors and industry watchers, Oncoinvent's progress is a case study in execution. The company is not only advancing a novel scientific platform but is also demonstrating the operational savvy required to navigate the complex logistics of global clinical trials. As the trial progresses towards its final data readout, all eyes will be on whether this promising alpha therapy can deliver a new standard of care for women fighting ovarian cancer.